- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Abivax SA (ABVX)
The Abivax SA share price today is 108.50, view EPA ABVX stock exchange data. Track the latest Abivax SA share price with real-time updates on ABVX stock performance including market cap, day range, 52-week range and dividend yield. Access ABVX charts, earnings dates and analyst estimates to support your investment decisions.
Currency in EUR
108.50
+0.10(+0.09%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
103.00
109.10
52 wk Range
57.50
139.00
ABVX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
103.00109.10
52 wk Range
57.50139.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABVX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
138.56
Upside
+27.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Abivax ADR receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Abivax ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 138.56
(+27.71% Upside)
Earnings
Latest Release
22-05-2026
EPS / Forecast
-0.61 / -0.80
Revenue / Forecast
1.3M / 428.87K
Compare ABVX to Peers and Sector
Metrics to compare | ABVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABVXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −28.1x | −3.0x | −0.3x | |
PEG Ratio | 0.52 | −0.10 | 0.00 | |
Price/Book | 21.8x | 0.1x | 2.6x | |
Price / LTM Sales | 1,899.2x | 20.4x | 2.9x | |
Upside (Analyst Target) | 29.6% | 145.2% | 56.7% | |
Fair Value Upside | Unlock | 3.8% | 10.2% | Unlock |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Abivax SA (ABVX) Share Price Today?
The Abivax SA share price today is 108.50.
What is the current Abivax SA (ABVX) share price and day range?
As of 30-07-2026, the Abivax SA share price is 108.50, with a previous close of 108.40. The share price has ranged from 103.00 to 109.10 today, while the 52-week range spans from 57.50 to 139.00.
What Is the Abivax SA Market Cap?
As of today, Abivax SA market cap is 9.34B.
What Is the Abivax SA (ABVX) Share Price Target?
The average 12-month share price target for Abivax SA is 138.56, with a high estimate of 180 and a low estimate of 70. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +27.71% Upside potential.
What Is Abivax SA's Earnings Per Share (TTM)?
The Abivax SA EPS (TTM) is -4.52.
When Is the Next Abivax SA Earnings Date?
Abivax SA will release its next earnings report on 21-09-2026.
From a Technical Analysis Perspective, Is ABVX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
What Stock Exchange Does Abivax SA Trade On?
Abivax SA is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Abivax SA?
The stock symbol for Abivax SA is "ABVX."
How Many Times Has Abivax SA Stock Split?
Abivax SA has split 0 times.
How Many Employees Does Abivax SA Have?
Abivax SA has 80 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.